Conditions: Seasonal Allergic Rhinitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 39
Healthy volunteers: no

Brief summary:
The investigators hypothesize that treatment with QNASL will reduce nasal mucosal inflammation induced by the allergy season and prevent the changes in the microbiome caused by the allergy season.

Detailed description:

Arms:
arm 1: QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment arm 2: Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment

Interventions: intervention 1: QNASL intervention 2: Placebo nasal spray
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: